Company Profile
Business Strategy
Corporate Factsheet
Management
Contact
Imprint
Webcast of the MediGene AG to Discuss the Results Obtained in a Clinical Phase II Trial of EndoTAG®-1 on April 7, 2008 at
4 PM (CEST)



MediGene Presents 3-Months Report 2008  more
European Regulatory Authority (EMEA) Recommends Granting of Marketing Authorization for MediGene's Drug Oracea®  more
MediGene Presents Details of the Excellent Clinical Efficacy Data Obtained with EndoTAG(TM)-1 in the Indication Pancreatic Carcinoma  more

MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases. MediGene pursues the strategy of integrating all core
areas of a modern biopharmaceuticals company from research to
drug development and commercialization.